.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,244,705

« Back to Dashboard

Details for Patent: 7,244,705

Title:Polyacid glycopeptide derivatives
Abstract: Disclosed are derivatives of glycopeptides that are substituted at the C-terminus with a substituent that comprises two or more (e.g. 2, 3, 4, or 5) carboxy (CO.sub.2H) groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Linsell; Martin S. (San Mateo, CA), Judice; J. Kevin (El Granada, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Filing Date:Apr 25, 2006
Application Number:11/410,549
Claims:1. A compound of formula II: ##STR00011## wherein: R.sup.17 is a dicarboxy-substituted alkyl group having from 3 to 10 carbon atoms; R.sup.18 is selected from the group consisting of hydrogen and alkyl group; R.sup.20 is selected from --CH.sub.2CH.sub.2CH.sub.2--NH--(CH.sub.2).sub.8CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--NH--(CH.sub.2).sub.7CH.sub.3; --CH.sub.2CH.sub.2--NHSO.sub.2--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2--NHSO.sub.2--(CH.sub.2).sub.11CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.10CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.3CH.dbd.CH--(CH.sub.2).sub.- 4CH.sub.3 (trans); --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.7CH.sub.3; --CH.sub.2CH.sub.2--S(O)--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.6Ph; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8Ph; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8Ph; --CH.sub.2CH.sub.2--NH--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2--NH--CH.sub.2-4-[4-(CH.sub.3).sub.2CHCH.sub.2--]-Ph; --CH.sub.2CH.sub.2--NH--CH.sub.2-4-(4-CF.sub.3-Ph)-Ph; --CH.sub.2CH.sub.2--S--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2--S(O)--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2--S(O)--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2-4-[3,4-di-Cl-PhCH.sub.2O--)-Ph; --CH.sub.2CH.sub.2--NHSO.sub.2--CH.sub.2-4-[4-(4-Ph)-Ph]-Ph; --CH.sub.2CH.sub.2CH.sub.2--NHSO.sub.2--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2--NHSO.sub.2--CH.sub.2-4-(Ph-C.ident.C--)-Ph; --CH.sub.2CH.sub.2CH.sub.2--NHSO.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2NHSO.sub.2-4-(naphth-2-yl)-Ph; 4-(4-chlorophenyl)benzyl; and 4-(4-chlorobenzyloxy)benzyl; or a pharmaceutically acceptable salt, or stereoisomer thereof.

2. The compound of claim 1, wherein R.sup.20 is selected from --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.10CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.3--CH.dbd.CH--(CH.sub.2).su- b.4CH.sub.3 (trans); --CH.sub.2CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.7CH.sub.3; --CH.sub.2CH.sub.2--S(O)--(CH.sub.2).sub.9CH.sub.3; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.6Ph; --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8Ph; --CH.sub.2CH.sub.2CH.sub.2--S--(CH.sub.2).sub.8Ph; --CH.sub.2CH.sub.2--S--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2--S(O)--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2-4-(4-Cl-Ph)-Ph; --CH.sub.2CH.sub.2CH.sub.2--S(O)--CH.sub.2-4-(4-Cl-Ph)-Ph; and --CH.sub.2CH.sub.2CH.sub.2--S--CH.sub.2-4-[3,4-di-Cl-PhCH.sub.2O--)-Ph.

3. The compound of claim 1, wherein R.sup.20 is --CH.sub.2CH.sub.2--S--(CH.sub.2).sub.9CH.sub.3.

4. The compound of claim 1, wherein R.sup.20 is 4-(4-chlorophenyl)benzyl.

5. The compound of claim 1, wherein R.sup.20 is 4-(4-chlorobenzyloxy)benzyl.

6. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of any one of claims 1, and 2 5.

7. A method of treating a bacterial disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound of any one of claims 1, and 2 5.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc